Pyrazinamide resistance in multidrug-resistant strains of Mycobacterium tuberculosis isolated in Abkhazia
| Autor: | Pardini M., Varaine F., Hewison C., Iona E., Pataracchia M., Orefici G., Fattorini L., Oggioni M. R., Meacci F., D'Amato V., Andrew P. W., Barer M., Yesilkaya H., Rinder H., Rusch-Gerdes S., Niemann S., Orru G., Bonnet M., Jarosz T. |
|---|---|
| Přispěvatelé: | Pardini M., Varaine F., Hewison C., Iona E., Pataracchia M., Orefici G., Fattorini L., Oggioni M.R., Meacci F., D'Amato V., Andrew P.W., Barer M., Yesilkaya H., Rinder H., Rusch-Gerdes S., Niemann S., Orru G., Bonnet M., Jarosz T. |
| Rok vydání: | 2007 |
| Předmět: |
Pharmacology
biology business.industry Antitubercular Agents Drug resistance Microbial Sensitivity Tests Mycobacterium tuberculosis Pyrazinamide biochemical phenomena metabolism and nutrition biology.organism_classification bacterial infections and mycoses Microbiology Multiple drug resistance Infectious Diseases Oncology Drug Resistance Multiple Bacterial medicine Pharmacology (medical) tuberculosis drug resistance business medicine.drug |
| Zdroj: | Journal of chemotherapy (Florence, Italy). 19(1) |
| ISSN: | 1120-009X |
| Popis: | The emergence of multidrug-resistant (MDR) Mycobacterium tuberculosis (Mtb) strains, i.e. strains resistant at least to isoniazid (INH) and rifampin (RMP), the two most powerful first-line drugs for the treatment of tuberculosis (TB), represents a worldwide health care problem. Patients with MDR strains should receive therapy based on individual drug susceptibility testing (DST) 1 including residual first-line (streptomycin, SM; ethambutol, EMB; and pyrazinamide, PZA) and second-line (ofloxacin, kanamycin, capreomycin, ethionamide, p-aminosalicylic acid, cycloserine) anti-TB drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|